Affigen Overview

Founded 2016
Status Private
Latest Deal Type Series A
Latest Deal Amount $17M
Latest Deal Amount
Investors 2

Affigen General Information


Developer of tumor-identifying therapies designed to treat cancer. The company is engaged in developing therapeutics targeting cell lineage-specific tumor proteins that maximize both anti-tumor activity and safety in patients with critically unmet medical needs, enabling the patients to combat against cancer with extreme sensitivity and precision.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Primary Office
  • 20 South Sarah Street
  • Saint Louis, MO 63108
  • United States
+1 (314) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Affigen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 21-Feb-2017 $17M 0000 Completed Pre-Clinical Trials
1. Seed Round 01-Jan-2016 Completed Startup

Affigen Executive Team (3)

Name Title Board Seat Contact Info
Carlos Santos Ph.D Co-Founder & Chief Executive Officer
Jonathan Feldmann Chief Operating Officer
David States Ph.D Chief Medical Officer

Affigen Investors (2)

To view Affigen‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Black Beret Life Sciences Venture Capital Minority 000 0000 000000 0
Frameshift (Missouri) Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial